Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer

• Main Authors: Bo Lin (Author), Bing Lu (Author), I-yun Hsieh (Author), Zhen Liang (Author), Zicheng Sun (Author), Yang Yi (Author), Weiming Lv (Author), Wei Zhao (Author), Jie Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundAnaplastic thyroid cancer is the most aggressive thyroid cancer and has a poor prognosis. At present, there is no effective treatment for it.MethodsHere, we used different concentrations of GSK-J4 or a combination of GSK-J4 and doxorubicin to treat human Cal-62, 8505C, and 8305C anaplastic...